Overview
Singapore has no peptide-specific statute, but peptide drugs fall squarely within the general medicines framework: they are treated as therapeutic products under the Health Products Act, administered by the Health Sciences Authority (HSA), and must be registered before they can be supplied, with importers and suppliers needing a dealer's licence. Clinically used peptides such as GLP-1 receptor agonists (semaglutide class) are prescription-only and may only be dispensed by a registered doctor or licensed pharmacy against a valid prescription; selling or advertising them online is prohibited. Unlicensed import, manufacture or supply of unregistered health products is a criminal offence carrying substantial fines and imprisonment, and HSA runs continuous e-commerce surveillance and enforcement. Lawful access exists only through a prescribing clinician (including named-patient supply of unregistered products) or limited personal-import allowances for one's own prescribed medication.
Key Points
- Peptide medicines are regulated as therapeutic products under the Health Products Act and its Health Products (Therapeutic Products) Regulations 2016, and every therapeutic product must be registered with HSA before it can be supplied in Singapore, with a dealer's licence required to manufacture, import or supply. [1]
- GLP-1 receptor agonist peptide drugs used for diabetes and weight loss are prescription-only medicines that may only be dispensed by a registered medical practitioner or a licensed retail pharmacy to a patient holding a valid prescription, and are barred from advertisement and sale on local online platforms. [2]
- Since 2022 HSA has investigated 16 cases of unauthorised sale or illegal advertising of GLP-1 receptor agonist drugs and had a further 82 non-compliant listings removed from e-commerce platforms. [2]
- Selling or supplying illegal (including unregistered) health products in Singapore attracts penalties of up to a S$100,000 fine and/or up to three years' imprisonment under the Health Products Act. [4]
- Personal import of prescribed medication is capped at three months' supply, each medication must be in its original container labelled by the dispensing pharmacy with the patient's name, and the traveller is responsible for checking whether the item is prohibited or contains a controlled substance requiring prior HSA approval. [3]
- An unregistered therapeutic product can still be lawfully imported and supplied in limited circumstances under HSA's named-patient framework, which is restricted to qualified practitioners and registered pharmacists and carries record-keeping and labelling obligations. [5]
- Enforcement remains active into 2026: between 10 and 23 March 2026 HSA removed 959 illegal health product listings from local e-commerce and social media platforms and issued warnings to 152 sellers, with importers, manufacturers and suppliers liable to a fine of up to SGD 100,000 and/or three years' imprisonment. [6]
- No Singapore statute or scheduling instrument naming research peptides such as BPC-157 or TB-500 specifically was located in this research; their restricted status is an inference from the general Health Products Act therapeutic-product regime and Poisons Act framework rather than from a peptide-specific legal source. (No reliable source found for this point -- flagged as unverified rather than stated as fact.)